Water covers some 75% of the earth’s surface, while land covers 25%, approximately. Yet the former accounts for less than 1% of world GDP, the latter 99% plus. Part of the reason for this imbalance is that there are more people located on land than water. But a more important explanation is that while land is privately owned, water is unowned (with the exception of a few small lakes and ponds), or governmentally owned (rivers, large lakes). This gives rise to the tragedy of the commons: when something is unowned, people have less of an incentive to care for it, preserve it, and protect it, than when they own it. As a result we have oil spills, depletion of fish stocks, threatened extinction of some species (e.g. whales), shark attacks, polluted and dried-up rivers, misallocated water, unsafe boating, piracy, and other indices of economic disarray which, if they had occurred on the land, would have been more easily identified as the result of the tragedy of the commons and/or government ownership and mismanagement. The purpose of this book is to make the case for privatization of all bodies of water, without exception. In the tragic example of the Soviet Union, the 97% of the land owned by the state accounted for 75% of the crops. On the 3% of the land privately owned, 25% of the crops were grown. The obvious mandate requires that we privatize the land, and prosper. The present volume applies this lesson, in detail, to bodies of water.
With an emphasis on the fundamental and practical aspects of ADME for therapeutic proteins, this book helps readers strategize, plan and implement translational research for biologic drugs. • Details cutting-edge ADME (absorption, distribution, metabolism and excretion) and PKPD (pharmacokinetic / pharmacodynamics) modeling for biologic drugs • Combines theoretical with practical aspects of ADME in biologic drug discovery and development and compares innovator biologics with biosimilar biologics and small molecules with biologics, giving a lessons-learned perspective • Includes case studies about leveraging ADME to improve biologics drug development for monoclonal antibodies, fusion proteins, pegylated proteins, ADCs, bispecifics, and vaccines • Presents regulatory expectations and industry perspectives for developing biologic drugs in USA, EU, and Japan • Provides mechanistic insight into biodistribution and target-driven pharmacokinetics in important sites of action such as tumors and the brain
The undisputed gold standard text in the field, Ryan's Retina is your award-winning choice for the most current, authoritative information on new technologies, surgical approaches, scientific advances and diagnostic and therapeutic options for retinal diseases and disorders. Packed with timely updates throughout, new illustrations, and a dedicated team of editors who extend Dr. Ryan’s legacy in retina, this outstanding 6th Edition is a must-have reference for retinal specialists, ophthalmologists, and fellows in training. Offers the most comprehensive content available on retina, balancing the latest scientific research and clinical correlations, covering everything you need to know on retinal diagnosis, treatment, development, structure, function, and pathophysiology. Provides a truly global perspective from five highly esteemed section editors and more than 350 other world authorities from across Europe, Asia, Australasia, and the Americas. Bullets Includes new chapters on widefield imaging, intraoperative OCT imaging, medical management of diabetes mellitus and age-related macular degeneration, and senile retinoschisis. Includes more than 1,150 brand-new illustrations, scans, and photographs throughout. Covers the explosion of new imaging options across optical coherence tomography (OCT), fundus imaging, and autofluorescence imaging, including a greatly expanded OCT imaging chapter that features crucial information on OCT-Angiography (OCT-A). Presents new pharmacotherapy data and the latest approaches in anti-VEGF therapy for age-related macular degeneration, diabetic retinopathy, and venous occlusive disease. Contains thorough content updates in every area of retina, including advanced imaging technologies, gene therapy, inflammation and immune responses, white dot syndromes, epigenetic mechanisms, transplantation frontiers to improve retinal function, macular hole, myopic eye disease, ocular trauma, drug delivery to the posterior segment, advances in macular surgery, vitrectomy and complex retinal detachment, tumors, and retinal genetics and biology.
A brief introductory description of the new physical and mathematical ideas involved in formulating supersymmetric theories. The basic ideas are worked out in low space dimensionalities and techniques where the formulae do not obscure the concepts.
2015 BMA Medical Book Awards Highly Commended in Oncology Category!The Molecular Basis of Cancer arms you with the latest knowledge and cutting-edge advances in the battle against cancer. This thoroughly revised, comprehensive oncology reference explores the scientific basis for our current understanding of malignant transformation and the pathogenesis and treatment of this disease. A team of leading experts thoroughly explains the molecular biologic principles that underlie the diagnostic tests and therapeutic interventions now being used in clinical trials and practice. Detailed descriptions of topics from molecular abnormalities in common cancers to new approaches for cancer therapy equip you to understand and apply the complexities of ongoing research in everyday clinical application. - Effectively determine the course of malignancy and design appropriate treatment protocols by understanding the scientific underpinnings of cancer. - Visually grasp and retain difficult concepts easily thanks to a user-friendly format with abundant full-color figures. - Find critical information quickly with chapters following a logical sequence that moves from pathogenesis to therapy. - Stay current with the latest discoveries in molecular and genomic research. Sweeping revisions throughout include eight brand-new chapters on: Tumor Suppressor Genes; Inflammation and Cancer; Cancer Systems Biology: The Future; Biomarkers Assessing Risk of Cancer; Understanding and Using Information About Cancer Genomes; The Technology of Analyzing Nucleic Acids in Cancer; Molecular Abnormalities in Kidney Cancer; and Molecular Pathology. - Access the entire text and illustrations online, fully searchable, at Expert Consult.
This will help us customize your experience to showcase the most relevant content to your age group
Please select from below
Login
Not registered?
Sign up
Already registered?
Success – Your message will goes here
We'd love to hear from you!
Thank you for visiting our website. Would you like to provide feedback on how we could improve your experience?
This site does not use any third party cookies with one exception — it uses cookies from Google to deliver its services and to analyze traffic.Learn More.